Valproate
- PDF / 169,649 Bytes
- 1 Pages / 595.245 x 841.846 pts (A4) Page_size
- 0 Downloads / 123 Views
1
S
Hyperammonaemia syndrome: case report A 59-year-old woman developed hyperammonaemia syndrome during treatment with valproate for CreutzfeldtJakob disease. The woman, who had a history of spinal stenosis, presented to a hospital with confusion, ataxia and aphasia. After various examinations, she was diagnosed with Creutzfeldt-Jakob disease. Due to lack of effective treatment for the condition, she was initially started on phenytoin. However, she continued to experience intermittent seizure activity. Hence, valproate [route and dosage not stated] was added to the ongoing phenytoin therapy. However, she developed valproate therapy related hyperammonaemia syndrome [duration of treatment to reaction onset not stated]. Consequently, the woman’s valproate therapy was replaced by levetiracetam [outcome not stated]. Despite the treatment with levetiracetam and phenytoin, her underlying condition continued to deteriorate, and she continued to experience seizure activity with myoclonus. Subsequently, she was discharged to an inpatient hospice care. Author comment: "Valproate was added, but the patient developed valproate [hyperammonaemia] syndrome and was switched to intravenous levetiracetam." Miller M. Prion Problem: A Rapidly Progressive Dementia. American Journal of Medicine 133: 58-59, No. 1, Jan 2020. Available from: URL: http:// 803444182 doi.org/10.1016/j.amjmed.2019.07.026 - USA
0114-9954/20/1785-0001/$14.95 Adis © 2020 Springer Nature Switzerland AG. All rights reserved
Reactions 4 Jan 2020 No. 1785
Data Loading...
